Psyence Biomedical Ltd

Psyence Biomedical Ltd (PBM) Stock Analysis

$0.000

-0.000 (-100.00%)At close

Loading chart…
High
4.370
Open
4.370
VWAP
2.85
Vol
14.69K
Mkt Cap
—
Low
4.185
Amount
41.89K
EV/EBITDA, TTM
0.00

Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.

psyencebiomed.com/contact

AI analysis of Psyence Biomedical Ltd (PBM)

hold

Psyence Biomedical Ltd is currently priced at $4.57, which is relatively stable but shows a 2.41% increase recently. However, the company reported a significant net loss of $753,254 in Q2 2026, indicating financial challenges. The RSI is at 58.53, suggesting the stock is neither overbought nor oversold, but the forward P/E ratio is at 0, indicating uncertainty in future earnings. While there are positive catalysts such as U.S. government support for ibogaine development, the financial performance raises concerns, making it a hold rather than a buy.

Valuation Metrics

The current forward P/E ratio for Psyence Biomedical Ltd (PBM) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
Overvalued
0.00
Undervalued
0.00

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued
0.00
Undervalued
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
Overvalued
0.00
Undervalued
0.00

Alphio AI Price Scenarios for PBM

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%PBM

$4.72

Scenario price

B

Base

Base · 50%PBM

$4.52

Scenario price

B

Bear

Bear · 25%PBM

$4.35

Scenario price

Events Timeline

2026-08-26 (ET)

06:30:00

Selling Stockholders Plan to Sell 1.15M Common Shares

2026-05-15 (ET)

09:30:00

Psyence BioMed to Visit U.S. to Promote Psychedelic Research

2026-04-20 (ET)

16:30:00

Major Averages Decline Amid Escalating Tensions with Iran

12:00:00

Major Averages Decline Amid Rising Tensions with Iran

08:10:00

Psyence Biomedical Updates Strategic Position in Global Ibogaine Market

Show More Events

News

Show More News

PBM FAQ — answered by Alphio AI

Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Psyence Biomedical Ltd is currently priced at $4.57, which is relatively stable but shows a 2.41% increase recently. However, the company reported a significant net loss of $753,254 in Q2 2026, indicating financial challenges. The RSI is at 58.53, suggesting the stock is neither overbought nor oversold, but the forward P/E ratio is at 0, indicating uncertainty in future earnings. While there are positive catalysts such as U.S. government support for ibogaine development, the financial performance raises concerns, making it a hold rather than a buy.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started